Imhoff John E 4

4 · GUIDED THERAPEUTICS INC · Filed Apr 7, 2026

AI-generated summary of this filing

Updated Apr 7, 2026

GUIDED THERAPEUTICS (GTHP) 10% Owner John Imhoff Acquires Shares

What Happened

John E. Imhoff (reported as a 10% owner) acquired common shares through conversions and received a stock award. Key items: 157,417 shares were issued on March 31, 2026, upon conversion of a convertible promissory note at $0.07/share (aggregate $11,019.18); on March 26, 2026 he converted 10 shares of Series F preferred into 40,000 common shares; 2,157 common shares were issued as payment of accrued dividends on Series F preferred; and on March 10, 2026 he was granted 110,000 shares subject to vesting (one‑quarter vested immediately = 27,500 shares).
These actions are acquisitions by conversion/award (not open‑market buys). The promissory-note conversion was inexpensive ($0.07 per share) and a portion of the award remains unvested and subject to continued service.

Key Details

Transaction dates and prices:
- Mar 10, 2026 — Award of 110,000 shares at $0.00 (derivative award). One‑quarter (27,500) vested on Mar 10, 2026; remaining vest monthly beginning Jun 10, 2026, fully vesting Mar 10, 2029. (Footnote F1)
- Mar 26, 2026 — 2,157 common shares issued for accrued dividends on Series F preferred (conversion price $0.2773). (F2)
- Mar 26, 2026 — Converted 10 shares of Series F preferred into 40,000 common shares (Series F stated value $1,000, conversion price $0.25). (F3)
- Mar 31, 2026 — Converted $11,019.18 of a Sept 25, 2025 convertible promissory note into 157,417 common shares at $0.07/share. (F4)
Aggregate reported common shares acquired (including grant): 309,574 shares (199,574 common issued by conversion/dividend + 110,000 award). Of the 110,000 award, 27,500 vested immediately.
Amount paid for conversion: $11,019.18 (for the 157,417‑share conversion). The preferred conversion and dividend‑paid shares involved no cash purchase by Mr. Imhoff.
Remaining debt: $110,000 principal remains outstanding under the convertible note; upon an event of default that balance may convert at a variable conversion price. (F4)
The filing was made April 7, 2026 for transactions occurring in March 2026 (the filing appears late relative to typical Form 4 timing).

Context

These were not open‑market purchases but conversions of securities and a time‑based equity award. Conversions and awards often reflect financing, dividend conversions, or compensation mechanics rather than a direct market signal.
As a 10% owner, Imhoff is a significant shareholder; his transactions include both corporate financing/conversion activity and compensation vesting.

Form 4

Period: 2026-03-10

Director10% Owner

Transactions

Other
Common Stock
[F2]
2026-03-26+2,157→ 21,055,256 total
Other
Preferred Series F Stock
[F3]
2026-03-26−10→ 0 total
Other
Common Stock
[F3]
2026-03-26+40,000→ 21,095,256 total
Conversion
Common Stock
[F4]
2026-03-31$0.07/sh+157,417$11,019→ 21,252,673 total
Award
Stock Options
[F1]
2026-03-10+110,000→ 110,000 total
Exercise: $0.29Exp: 2036-03-09→ Common Stock (110,000 underlying)
Conversion
Convertible Promissory Note
[F4]
2026-03-31$0.07/sh−157,417$11,019→ 110,000 total
Exercise: $0.07From: 2026-03-31Exp: 2027-02-28→ Common Stock (156,086 underlying)

Footnotes (4)

[F1]One-fourth of the shares subject to the award vested on March 10, 2026; the remaining shares will vest monthly, starting on June 10, 2026, subject to the reporting person's continued service on each such date, until the award is fully vested on March 10, 2029.
[F2]These shares were issued for payment of accrued dividends on the reporting individual's Series F preferred stock, at a conversion price of $0.2773.
[F3]On March 26, 2026, Mr. Imhoff converted 10 shares of Series F preferred stock into 40,000 shares of common stock. The Series F preferred stock had a stated value of $1,000 and $0.25 conversion price.
[F4]On March 31, 2026, Dr. Imhoff converted $11,019.18 outstanding under a September 25, 2025 Convertible Promissory Note into 157,417 shares of common stock at a conversion price of $0.07 per share. The amount converted consisted of $10,000 of principal and $1,019.18 of accrued interest. Following the reported conversion, $110,000 of principal remains outstanding under the convertible promissory note. Upon the occurrence of an event of default, the remaining balance is convertible into common stock at a variable conversion price determined in accordance with the terms of the note.

Signature

/s/ John E. Imhoff|2026-04-07

1 file